CF Finance Acquisition Corp.

This is the extension vote, NOT the GCM Grosvenor deal vote, which runs on the separate proxy statement/prospectus — conflating them inverts what a holder must do, since redeeming here exits before the transaction. The Class A count on the record date is 28,264,713, down from 28,858,413 in June, so the first extension already cost the trust some shares. No new sponsor contribution per share is stated in this preliminary, in contrast to the $0.09 promised in June by separate additional proxy material.

The condition to watch is cash: the Grosvenor side need not close unless Available Acquiror Cash in the trust is at least $300,000,000 counting the PIPE subscriptions and the sponsor's amended forward purchase, or at least $75,000,000 without them, in each case after redemptions. CFFA must also hold $5,000,001 of net tangible assets at closing. The structure leaves public holders with about 21.4% of Grosvenor Capital held through the surviving corporation rather than a direct interest in the manager.

A self-reported, self-inflicted listing deficiency with a defined cure window rather than a delisting threat — the fix is appointing one independent director, which the June 22 report already said the board expected to do. It is worth reading the two reports together: the same appointment that broke the rule was disclosed as routine four days earlier. Note the document describes Pion as 'the Company's Chief Executive Officer', while the June 22 report identifies him as Chief Financial Officer and Howard Lutnick as CEO.

Adding an executive officer who is also a Cantor Fitzgerald senior manager to a Cantor-sponsored SPAC's board tips the board away from an independent majority, which the report itself flags by promising an independent appointment to follow. That consequence is not hypothetical: two days later the Company notified Nasdaq that the appointment put it out of compliance with the board-composition listing rule. Nothing here touches the trust, the deadline or a target.

The extension is executed, not merely authorised, and the price of it is on the record: 593,700 shares out at about $10.27, roughly $6.1 million leaving the trust, against a $2,489,824.17 sponsor deposit going in. That deposit is the $0.09 per unredeemed share promised on June 5, 2020, and it is a loan — non-interest-bearing, repayable in full on consummation, with up to $750,000 convertible into sponsor-style private placement warrants at $1.00.

The report gives holders the exact price of waiting: $0.09 per unredeemed public share, contingent on the extension passing, taking the stated per-share trust from about $10.33 to about $10.42. That contribution is not a gift — it accrues no interest but is repayable to the sponsor in full on consummation of a business combination, so it is a loan sitting ahead of nothing but funded into the trust. Neither the extension nor the contribution had happened as at this report; both are conditional on the June 15, 2020 vote.

It changes the arithmetic of the election after the definitive proxy was mailed: a holder who redeems takes roughly $10.33, while a holder who stays is told to expect roughly $10.42. Both figures are the company's own approximations, and the contribution is conditional twice over — it is 'conditioned upon the implementation of the Extension', and it is only to be made 'by June 17, 2020' if the Extension is implemented, so it is contingent on the vote, not cash already in trust. A record carrying only the pre-contribution figure understates what non-redeeming holders were offered.

The only date a redeeming holder can act on moved: the preliminary's 8 Jun 2020 delivery deadline became 11 Jun 2020 in the definitive, so any note or calendar entry sourced to the preliminary is now wrong by three days. The record date did not move with it, which is the normal pattern but worth stating explicitly. There were 28,858,413 Class A and 7,064,603 Class B shares outstanding on the record date. The company still names no target: the board says only that there will not be sufficient time before 17 Jun 2020.

The shell is solvent only through its sponsor: management's answer to going concern is that the Sponsor has committed up to $750,000 by loan and has the wherewithal for $1,500,000 in aggregate. The document says the June 17, 2020 date MAY be extended by a shareholder vote 'the outcome of which is uncertain' - a proposal, not a date. Trust figures are March 31, 2020 balances and $10.10 is a carrying value, not a redemption price. Small inconsistency for a human: the cash-flow statement calls the trust assets held-to-maturity securities where the fair-value note calls them a money market fund.

This is a naked extension: the board says only that it is in discussions and that there will not be sufficient time before 17 Jun 2020, so a holder is being asked to wait without a named target. The proxy is unusual in stating the delivery deadline as a calendar date rather than a formula, which is the single most actionable fact in the document. Its redemption figure is hedged — the company 'anticipates that the per-share price at which public shares will be redeemed... will be approximately $10.33' — and no sponsor deposit is offered to raise it.

The delisting procedure initiated on December 17, 2019 is resolved inside three weeks, and the filing shows exactly what resolved it: one new independent director seated on the audit committee in place of a sponsor-related director. That is the remedy the company said it would apply, and it changes the board's composition rather than anything about the trust or the search. A new CFO was appointed on the same day.

The deficiency is board composition, not a financial or distribution test, and the company states its own remedy and timetable: one new independent director and two fewer sponsor-affiliated directors by early January 2020. The mechanical consequence is a reduction in sponsor representation on the board of a SPAC that has not yet announced a transaction. The stay is automatic on the hearing request; the expectation that the hearing will be cancelled is the company's, based on staff discussions, not a Nasdaq determination.

This is a routine annual meeting; nothing on the agenda concerns the business combination deadline, an extension or redemption rights. The advance-notice deadline of December 2, 2019 disclosed in the company's November 22 Item 5.08 report governs any additional nomination or proposal at this meeting.

An Item 5.08 filing is required because the meeting date moved more than 30 days from the anniversary of the prior year's meeting, which resets the advance-notice window — here to December 2, 2019, ten days after the announcement. That is the operative deadline for any stockholder nomination or proposal at the December 18 meeting. The report says nothing about a business combination.

Redemption value is disclosed on the face of the balance sheet at $10.10 per share rather than $10.00 — this SPAC's trust was funded above the unit price, so the floor sits above par. The company was operating on sponsor credit: $167,985 of cash against a $2,825,841 sponsor note and accrued liabilities that grew to $997,317 from $28,169. The redeemable share count rose by 1,111,352 through reclassification.

Accrued liabilities rose more than fortyfold in six months while the company's own cash halved — deal costs are accumulating faster than the sponsor loan is being drawn.

The trust is now fully funded at $10.10 per share, but $2,825,841 of that was lent by the sponsor and is repayable at closing — so the economic trust available to a target is lower than the redemption value suggests.

Records a $30,000,000 committed forward purchase from the sponsor that would fund at closing regardless of redemptions — capital that sits outside the trust and outside the redemption math.

Completes the offering with the over-allotment fully taken up and the $10.10 per-share trust value maintained, at the cost of $2,825,841 of sponsor loans that must be repaid or converted at closing.

Confirms the $10.10 per-share redemption value is held through the partial over-allotment, with the sponsor lending the ten-cent premium on the new shares as well.

Establishes a trust of $252.5 million against 25,000,000 public shares — $10.10 per share — funded above the offering price by sponsor money that the sponsor is repaid for only at closing.

Funds the trust from three sources — public proceeds, a private unit placement and a sponsor loan — so the per-share trust figure exceeds what the public units alone contributed.

Three-quarters of a warrant per unit is a fraction this platform's models do not carry: it sits between the one-half and the whole warrant, and a holder needs four units to hold three exercisable warrants. The trust is funded at $10.10 on a $10.00 unit, so the floor starts above the offering price, and part of that top-up comes from a sponsor LOAN rather than from the offering - a claim against the company, not against the trust. The call is the standard $0.01 / 30 days / last reported sale price at or above $18.00 for 20 of 30 trading days, and charter amendments need 65%.